(Q33752776)

29 July 2017

1 reference

title

The treatment of obesity in type 2 diabetes mellitus (English)

1 reference

29 July 2017

0 references

1 reference

Gumbiner B

1

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Primary Care: Clinics in Office Practice

29 July 2017

published in

1 reference

29 July 2017

volume

26

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

869-883

1 reference

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Metabolic implications of body fat distribution

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Appetite Suppressants and Valvular Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Benefits and limitations of very-low-calorie diet therapy in obese NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

The prevention and treatment of obesity. Application to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Exercise as an adjunct to weight loss and maintenance in moderately obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Physical activity and long-term maintenance of weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Reduced rate of energy expenditure as a risk factor for body-weight gain

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: a five-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Behavioral treatment of obesity. Its application to type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2805%2970136-6

7 January 2021

10.1016/S0095-4543(05)70136-6

Identifiers

DOI

1 reference

29 July 2017

1 reference